In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
Phase 3positiveamivantamabamivantamab-chemotherapyPositive
AI Analysis
Summary
Phase III PAPILLON study demonstrates that first-line amivantamab plus chemotherapy achieves median overall survival of 34.3 months in EGFR Exon 20 insertion-positive advanced NSCLC, the longest reported for this indication compared to 27.9 months with chemotherapy alone.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Final overall survival analysis: median 34.3 months with amivantamab-chemotherapy versus 27.9 months with chemotherapy alone; longest overall survival reported for EGFR Exon 20 insertion-positive advanced NSCLC
Importance:8/10
Sentiment:
0.85
oncologyNSCLCamivantamabEGFRPhase 3overall survivalfirst-line
Read the original article
Published by PR Newswire Clinical Trials on September 14, 2026 11:14 AM